Figure 3.
Association of tissue-type plasminogen activator to measures of disease progression, and other markers in the plasminogen pathway. A) Disease duration; B) D4Z4 fragment size; C) serpin peptidase inhibitor; and D) vitronectin.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.